Dierickx_EU Haematology 03/03/2010 14:37 Page 15
The Use of Rituximab in Immune-mediated Anaemia
1. Sonet A, Bosly A, Rituximab and chemotherapy in diffuse Leukemia, 2002;16(10):2092–5. 32. Ling HT, Field JF, Blinder MA, Sustained response with
large cell B cell lymphoma, Expert Rev Anticancer Ther, 17. Kaufman M, Limaye SA, Driscoll N, et al., A combination rituximab in patients with thrombotic thrombocytopenic
2009;9(6):719–26. of rituximab, cyclophosphamide and dexamethasone purpura: a report of 13 cases and review of the literature,
2. Gao G, Liang X, Jiang J, et al., A systematic review and effectively treats immune cytopenias of chronic Am J Hematol, 2009;84(7):418–21.
meta-analysis of immunochemotherapy with rituximab lymphocytic leukemia, Leuk Lymphoma, 2009;50(6):892–9. 33. Scully M, Cohen H, Cavenagh J, et al., Remission in acute
for B-cell non-Hodgkin’s lymphoma, Acta Oncol, 18. Cooper N, Evangelista ML, Amadori S, et al. Should refractory and relapsing thrombotic thrombocytopenic
2010;49(1): 3–12. rituximab be used before or after splenectomy in purpura following rituximab is associated with a
3. McDonald V, Leandro M, Rituximab in non- patients with immune thrombocytopenic purpura? Curr reduction in IgG antibodies to ADAMTS-13, Br J Haematol,
haematological disorders of adults and its mode of Opin Hematol, 2007;14(6):642–6. 2007;136(3):451–61.
action, Br J Haematol, 2009;146(3):233–46. 19. Godeau B, Porcher R, Fain O, et al., Rituximab efficacy and 34. Foley SR, Webert K, Arnold DM, et al., A Canadian phase
4. Garvey B, Rituximab in the treatment of autoimmune safety in adult splenectomy candidates with chronic II study evaluating the efficacy of rituximab in the
haematological disorders, Br J Haematol, immune thrombocytopenic purpura: results of a management of patients with relapsed/refractory
2008;141(2):149–69. prospective multicenter phase 2 study, Blood, thrombotic thrombocytopenic purpura, Kidney Int Suppl,
5. Maloney DG, Smith B, Rose A, Rituximab: mechanism of 2008;112(4):999–1004. 2009;112:S55–58.
action and resistance, Semin Oncol, 2002;29 20. Norton A, Roberts I, Management of Evans syndrome, 35. Fakhouri F, Vernant JP, Veyradier A, et al., Efficiency of
(1 Suppl. 2):2–9. Br J Haematol, 2006;132(2):125–37. curative and prophylactic treatment with rituximab in
6. Semple JW, Freedman J, Autoimmune pathogenesis and 21. Michel M, Chanet V, Dechartres A, et al., The spectrum of ADAMTS13-deficient thrombotic thrombocytopenic
autoimmune hemolytic anemia, Semin Hematol, 2005;42(3): Evans’ syndrome in adults: new insight into the disease purpura: a study of 11 cases, Blood, 2005;106(6):1932–37.
122–30. based on the analysis of 68 cases, Blood, 2009;114(15): 36. George JN, Woodson RD, Kiss JE, et al., Rituximab therapy
7. Stasi R, Del Poeta G, Stipta E, et al., Response to B-cell 3167–72. for thrombotic thrombocytopenic purpura: a proposed
depleting therapy with rituximab reverts the 22. Sawada K, Fuiishima N, Hirokawa M, et al., Acquired pure study of the Transfusion Medicine/Hemostasis Clinical
abnormalities of T-cell subsets in patients with idiopathic red cell aplasia: updated review of treatment, Br J Trials Network with a systematic review of rituximab
thrombocytopenic purpura, Blood, 2007;110(8):2924–30. Haematol, 2008;142(4):505–14. therapy for immune-mediated disorders, J Clin Apher,
8. Stasi R, Cooper N, Del Poeta G, et al., Analysis of 23. Dungarwalla M, Marsh JC, Tooze JA, et al., Lack of clinical 2006;21:49–56.
regulatory T-cell changes in patients with idiopathic efficacy of rituximab in the treatment of autoimmune 37. Ram R, Ben-Bassat I, Shpilberg O, et al., The late adverse
thrombocytopenic purpura receiving B cell-depleting neutropenia and pure red cell aplasia: implications for events of rituximab therapy—rare but there! Leuk
therapy with rituximab, Blood, 2008;112(4):1147–50. their pathophysiology, Ann Hematol, 2007;86(3):191–7. Lymphoma, 2009;50(7):1083–95.
9. Kimby E, Tolerability and safety of rituximab (MabThera), 24. Ghazal H, Succesful treatment of pure red cell aplasia 38. Aksoy S, Dizdar O, Hayran M, et al., Infectious
Cancer Treat Rev, 2005;31(6):456–73. with rituximab in patients with chronic lymphocytic complications of rituximab in patients with lymphoma
10. Gehrs BC, Friedberg RC, Autoimmune hemolytic anemia, leukemia, Blood, 2002;99(3):1092–4. during maintenance therapy: a systematic review and
Am J Hematol, 2002;69(4):258–71. 25. Murrin RJ, Murray JA, Thrombotic thrombocytopenic meta-analysis, Leuk Lymphoma, 2009;50(3):357–65.
11. Dacie SJ, The immune haemolytic anaemias: a century of purpura: aetiology, pathophysiology and treatment, Blood 39. Pei SN, Chen CH, Lee CM, et al., Reactivation of hepatitis
exciting progress in understanding, Br J Haematol, Rev, 2006;20(1):51–60. B virus following rituximab-based regimens: a serious
2001;114(4):770–85. 26. George JN, Thrombotic thrombocytopenic purpura, complication in both HBsAg-positive and HBsAg-negative
12. Dierickx D, Verhoef G, Van Hoof A, et al., Rituximab in N Engl J Med, 2006;354(18):1927–35. patients, Ann Hematol, 2010;89(3):255–62.
auto-immune haemolytic anaemia and immune 27. Sadler JE, Thrombotic thrombocytopenic purpura: a 40. Yeo W, Chang TC, Leung NW, et al., Hepatitis B virus
thrombocytopenic purpura: a Belgian retrospective moving target, Hematology Am Soc Hematol Educ Program, reactivation in lymphoma patients with prior resolved
multicentric study, J Intern Med, 2009;266(5):484–91. 2006;415–20. hepatitis B undergoing anticancer therapy with or
13. Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for 28. Crowther MA, George JN, Thrombotic thrombocytopenic without rituximab, J Clin Oncol, 2009;27(4):605–11.
primary chronic cold agglutinin disease: a prospective purpura: 2008 update, Cleve Clin J Med, 2008;75(5):369–75. 41. Carson KR, Evens AM, Richey EA, et al., Progressive
study of 37 courses of therapy in 27 patients, Blood, 29. Sadler JE, Von Willebrand factor, ADAMTS13, and multifocal leukoencephalopathy after rituximab therapy
2004;103(8):2925–28. thrombotic thrombocytopenic purpura, Blood, in HIV-negative patients: a report of 57 cases from the
14. Schöllkopf C, Kjeldsen L, Bjerrum OW, et al., Rituximab in 2008;112(1):11–18. Research on Adverse Drug Events and Reports project,
chronic cold agglutinin disease: a prospective study of 30. Rock GA, Shumak KH, Buskard NA, et al., Comparison of Blood, 2009;113(20):4834–40.
20 patients, Leuk Lymphoma, 2006;47(2):253–60. plasma exchange with plasma infusion in the treatment 42. Liu X., Hong XN, Gu YJ, et al., Interstitial pneumonitis
15. Berentsen S, Ulvestad E, Langholm R, et al., Primary of thrombotic thrombocytopenic purpura. Canadian during rituximab-containing chemotherapy for non-
chronic cold agglutinin disease: a population based Apheresis Study Group, N Engl J Med, 1991;325(6):393–7. Hodgkin lymphoma, Leuk Lymphoma, 2008;49(9):1778–83.
clinical study of 86 patients, Haematologica, 31. Bennett C, Ha Luu T, Zakarija A, et al., Clinical and 43. Bitzan M, Anselmo M, Carpineta L, Rituximab (B-cell
2006;91(4):460–66. outcomes findings for thrombotic thrombocytopenic depleting antibody) associated lung injury (RALI): a
16. Gupta N, Kavuru S, Patel D, et al., Rituximab-based purpura among 467 persons with severely versus not pediatric case and systematic review of the literature,
chemotherapy for steroid-refractory autoimmune severely deficient ADAMTS-13 levels, Blood, Pediatr Pulmonol, 2009;44(9):922–34.
hemolytic anemia of chronic lymphocytic leukemia, 2007;110(11):2088a.
EUROPEAN HAEMATOLOGY 15
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100